FDA rejects Merck's Mevacor OTC bid

Share this article:

An FDA advisory panel has rejected Merck's bid to sell the cholesterol-lowering drug Mevacor without a prescription.

The panel voted 10-2 against recommending OTC sales of the drug.

The rejection marks the third time a global drugmaker has failed to win FDA approval for Mevacor's non-prescription status.

Merck's Edwin Hemwall VP, global OTC regulatory and scientific affairs. “We are disappointed in today's outcome.  We felt we presented a compelling case to the committee that non-prescription Mevacor 20 mg would be a valuable option for motivated consumers who know they have moderately elevated cholesterol and certain risk factors, and are already talking with their healthcare provider."
 
Although the FDA is not bound by its panel recommendations, it does take expert advice into consideration.  The anticipated action date by the FDA is Jan. 26, 2008.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.